Generated by AI
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy. Its lead product candidate, belapectin, is a galectin-3 inhibitor being studied in programs related to metabolic dysfunction-associated steatohepatitis, liver fibrosis, cirrhosis, and portal hypertension. The company also supports research into additional galectin-related treatments, including oral small-molecule inhibitors through collaborative efforts. Galectin Therapeutics is based in Norcross, Georgia, and operates within the biotechnology sector, where it focuses on discovery and development rather than commercial-scale product sales.
Website4960 Peachtree Industrial Boulevard
Norcross, GA, 30071
United States
The latest articles about GALT.
Tipranks Press Release.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Jul 9's posts. Generated by AI.
Summary of Dec 19's posts. Generated by AI.
Investors talking about GALT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.